Jun 22, 2021 Effect of Seladelpar and CB-0406 Combination Therapy on Obesity, Liver Fibrosis and Steatosis in a Diet-Induced Obese Mouse Model of Biopsy-Confirmed NASH With Fibrosis
Jun 22, 2021 Treatment With Seladelpar in Patients With Primary Biliary Cholangitis and Prior Experience With Obeticholic Acid or Fibrates
Jun 22, 2021 Efficacy, Safety, and Tolerability of Seladelpar in Patients With Compensated Liver Cirrhosis Due to Primary Biliary Cholangitis
Jun 22, 2021 An Independent Blinded Review of Suspected Drug Induced Liver Injury In NASH Patients by a Panel of Pathologists and Hepatologists
Mar 11, 2021 Quantitative assessment of NASH pathologies in 152 baseline H&E slides from a Phase 2 trial using the Path AI machine learning algorithm
Nov 13, 2020 A 52-Week Multi-Center Double-Blind Randomized Phase 2 Study of Seladelpar, a Potent and Selective Peroxisome Proliferator-Activated Receptor Delta (PPAR) Agonist, in Patients with Nonalcoholic Steatohepatitis (NASH)